Answers are grounded in this paper and cite their sources.
Hepatitis C virus (HCV) infection is an important cause of chronic liver disease in children and adolescents, despite its often asymptomatic and indolent course. In infants and children, infection is mainly acquired through vertical transmission, while horizontal transmission becomes increasingly relevant during adolescence. The introduction of direct-acting antivirals (DAAs) has revolutionised HCV management, providing highly effective and well-tolerated treatments. Current international guidelines recommend treatment for all children and adolescents aged ≥ 3 years with chronic HCV infection, preferably with pangenotypic, ribavirin-free regimens. Glecaprevir/pibrentasvir and sofosbuvir/velpatasvir are the main first-line options. Sofosbuvir plus daclatasvir represents an additional World Health Organization-recommended option, particularly in resource-limited settings. Despite these advances, early diagnosis, treatment adherence, and equitable access to DAAs remain essential to achieve HCV elimination in children.
No takes yet. Share an insight, caveat, or question.
Carrera et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: